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Background: Schistosomiasis is a neglected tropical disease and drug-repurposing is a useful strategy to fill its
exhausted drug development pipeline. The ferrocenyl analogue of chloroquine, ferroquine, is an antimalarial in
late-stage drug development. The aim of the present work was to study the antischistosomal activity of ferroquine
against Schistosoma mansoni adult worms and newly transformed schistosomula (NTS) in vitro and in vivo.
Hydroxyl-ferroquine and ruthenoquine were included to study the potential role of reactive oxygen species in
the antischistosomal activity. Chloroquine and mefloquine, the later described for its antischistosomal properties,
served as comparators.
Findings: All metal complexes were shown to be moderately cytotoxic on human cervix HeLa cancer cells and
human fetal lung fibroblasts MRC-5. 72 hours post-incubation NTS exposed to 33.3 μM ruthenoquine had died,
while ferroquine and hydroxyl-ferroquine treated worms were strongly affected. No activity was observed
treating NTS with chloroquine at 33.3 μM. Incubation of adult S. mansoni with 33.3 μM of the organometallic
derivatives were highly affected in viability but were still alive 72 hours post-incubation. Mefloquine showed the
highest activity against NTS and adult S. mansoni. Low total worm burden reductions of 0-36% were observed
following oral administration of 200–800 mg/kg of the ferroquine derivatives to S. mansoni-infected mice.
Conclusions: The organometallic compounds evaluated in this study revealed moderate in vitro activity against both
larval and adult stages of S. mansoni but low in vivo activity. No correlation can be drawn between the antimalarial and
antischistosomal activity of chloroquine analogues and oxidative shock does not seem to play a role in the activity of
these compounds against S. mansoni.
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Schistosomiasis is a neglected tropical disease, which
causes a considerable public health burden [1]. Millions
of people require treatment each year to prevent the
considerable health effects of schistosomiasis. For ex-
ample, in 2012 it has been estimated that 249 million
people should be treated in preventive chemotherapy pro-
grams [2]. Yet, treatment and control of schistosomiasis
relies on a single drug, namely praziquantel [1,3,4].
Research on novel antischistosomal drugs is nearly
exclusively driven by academic groups with a strong
focus on phenotypic approaches, since protein targets* Correspondence: jennifer.keiser@unibas.ch
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unless otherwise stated.are almost unknown [5]. Over the past years, libraries
consisting of existing drugs, so called drug-repurposing,
were investigated in order to fill the exhausted drug
development pipeline for schistosomiasis [6]. Drug re-
purposing circumvents the high cost of drug discovery
and development, the high failure rates and the long
duration to develop novel treatments by finding new
uses for compounds other than those they were ini-
tially intended to treat [7]. Antimalarials, in particular,
have been well studied, which is not surprising since
both Plasmodium and schistosomes degrade hemoglobin
[4]. For example, the excellent antischistosomal activity
of mefloquine (MQ, Figure 1) was demonstrated in
S. haematobium, S. japonicum and S. mansoni rodent
models [8]. The promising results obtained with MQ in
laboratory studies were followed up in clinical trials in
the past years [9,10]. Over the last decade, there hastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Chemical structures of chloroquine (CQ), mefloquine (MQ), ferroquine (FQ), hydroxyl-ferroquine (FQ-OH) and ruthenoquine (RQ).
Keiser et al. Parasites & Vectors 2014, 7:424 Page 2 of 7
http://www.parasitesandvectors.com/content/7/1/424been increasing interest in metal-based drugs and nu-
merous metal complexes have been synthesized and
evaluated as antimalarial agents [11]. The most promis-
ing candidate was undoubtedly the ferrocenyl analogue
of chloroquine (CQ, Figure 1), ferroquine (FQ, Figure 1).
FQ reached two different Phase IIb clinical trials, in
combination with artesunate or OZ439, for the treat-
ment of uncomplicated Plasmodium falciparum malaria
(http://www.mmv.org/research-development/project-
portfolio/oz439fq). FQ has a specific parasiticidal ef-
fect on Plasmodium due to the FQ-induced oxidative
stress within the digestive vacuole and the subsequent
destruction of the membrane resulting in death of the
parasite [12].
The aim of the present work was to study the anti-
schistosomal activities of FQ against S. mansoni in vitro
and in vivo. In addition, we investigated whether redox
activation plays a role in antischistosomal activity by
including the ruthenocenyl analogue of FQ, namely
ruthenoquine (RQ, Figure 1), which was shown, con-
trary to FQ, to be unable to produce reactive oxygen
species (ROS) in P. falciparum [13]. This difference in
redox activity was assumed to be responsible for the
greater antimalarial activity of FQ over RQ. Furthermore,
the antischistosomal activity of hydroxyl-ferroquine
(FQ-OH, Figure 1) was also studied since FQ-OH is
also able to produce hydroxyl radicals and provides re-
duced cytotoxic effects compared to FQ [14].
Findings
Methods
Animals and parasites
In vivo studies were carried out in accordance with
Swiss national and cantonal regulations on animal wel-
fare (permission no. 2070) at the Swiss Tropical and
Public Health Institute (Basel, Switzerland). Female mice
(NMRI strain, n = 31; weight ~ 20–22 g) were purchasedfrom Charles River, Germany, kept under environmentally-
controlled conditions (temperature ~ 25°C; humidity ~70%;
12-hour light and 12-hour dark cycle) with free access to
water and rodent diet and acclimatized for one week before
infection. Cercariae of S. mansoni were obtained from in-
fected intermediate host snails (Biomphalaria glabrata) as
described previously [15].Compounds
FQ, FQ-OH and RQ were synthesized according to re-
ported procedures [13,14,16]. MQ was kindly obtained
from Mepha AG (Aesch, Switzerland). CQ was purchased
from Sigma (Buchs, Switzerland). For in vitro studies,
compounds were dissolved in DMSO (Fluka, Buchs,
Switzerland) to obtain stock solutions of 10 mg/ml. For
in vivo studies, compounds were suspended in 7% (v/v)
Tween 80 and 3% (v/v) ethanol shortly before oral treat-
ment (10 ml/kg) of mice.In vitro studies
Newly transformed schistosomula (NTS)
S. mansoni cercariae were mechanically transformed to
newly transformed schistosomula (NTS) [17]. A NTS
suspension at a concentration of 100 NTS per 50 μl was
prepared using Medium 199 (Invitrogen, Carlsbad, CA)
[supplemented with 5% inactivated fetal calf serum (iFCS)
and 100 U/ml penicillin and 100 mg/mL streptomycin
(Invitrogen). NTS were incubated with 10 μM and
33.3 μM of the test compounds for 72 h. Compounds
were tested at least in triplicate and the highest concentra-
tion of DMSO served as control. Plates were incubated at
37°C, 5% CO2. NTS were evaluated by microscopic
readout (Carl Zeiss, Germany, magnification 80x) using
a viability scale scoring death, changes in motility, via-
bility, and morphological alterations [17].
Table 1 IC50 values for ferroquine (FQ), hydroxyl-ferroquine
(FQ-OH), ruthenoquine (RQ), chloroquine (CQ) and
mefloquine (MQ) in non-cancerous MRC-5 and HeLa
cancer cells
Complex IC50 MRC-5 (μM) IC50 HeLa (μM)
Cisplatin 7.9 ± 1.2 11.5 ± 2.9
FQ 24.4 ± 0.9 10.1 ± 0.3
FQ-OH 22.6 ± 1.2 16.8 ± 1.5
RQ 21.9 ± 2.6 8.8 ± 0.41
CQ 55.1 ± 1.3 87.0 ± 1.5
MQ 16.7 ± 0.2 6.7 ± 0.7
Cisplatin was used as positive control. Standard deviations are shown
in superscript.
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Adult schistosomes obtained from infected mice were
incubated in the presence of 10 μM and 33.3 μM of the
test compounds for up to 72 h. Phenotypes were moni-
tored daily based on motility, viability and morphological
alterations under an inverse microscope (Carl Zeiss,
Germany, magnification 80×).
Cytotoxicity studies
Cytotoxicity studies were performed on human cervix
HeLa cancer cells and non tumorigenic human fetal lung
fibroblasts MRC-5 to compare the activity of FQ, RQ,
FQ-OH, CQ, MQ and cisplatin. The cell viability was
determined via a colorimetric cell-based assay using
Resazurin (Promocell GmbH). Briefly, one day before
treatment cells were plated in triplicates in 96-well plates
at a density of 4 × 103 cells/well in 100 μl. Upon treating
cells with increasing concentrations of the target com-
plexes (freshly prepared stock solution in DMSO), cells
were incubated at 37°C/6% CO2 for 48 h, the medium
was removed, and 100 μl of complete medium containing
resazurin (0.2 mg/ml final concentration) was added.
After 4 h of incubation at 37°C/6% CO2, the fluorescence
of the highly red fluorescent resorufin product was quan-
tified at 590 nm emission with 540 nm excitation wave-
length in a SpectraMax M5 microplate Reader.
S. mansoni in vivo studies
Groups of 3–4 NMRI mice were treated orally with
single oral doses of 200 mg/kg of FQ, FQ-OH and RQ.
In addition, one group of mice was treated with a sin-
gle oral dose of 800 mg/kg FQ. Untreated mice served
as controls in all experiments. At 21 d post-treatment,
animals were killed by the CO2 method and dissected.
Worms were removed by picking, then sexed and
counted as previously described [18].
Statistics
Parasite viability values of treated and untreated worms
obtained from microscopic evaluation were averaged
(means (+/− standard deviation)) using Microsoft Excel
software. The Kruskal-Wallis test was applied for in vivo
studies, comparing the medians of the worm counts of
the treatment and control groups. A difference in median
was considered to be significant at a significance level
of 5% (StatsDirect statistical software, version 2.7.2.;
StatsDirect Ltd., United Kingdom).
Results and discussion
Cytotoxicity studies
We assessed the potential toxicity of the compounds
studied in this work on cervical cancer cells (HeLa) and
non-cancerous cells (MRC-5). Cisplatin, the best known
metal-based drug on the market was used as a reference.As shown in Table 1, all metal complexes were shown to be
moderately cytotoxic. MQ was the most toxic compound
in these assays. This is not surprising, since MQ is well
known for its adverse events, including gastrointestinal
effects [9] and neuropsychiatric toxicity [19]. On the other
hand, FQ was well tolerated and shown to be lacking rele-
vant adverse effects on central nervous system, respiratory,
renal, and gastrointestinal functions in a phase I trial [20].
However, larger trials are necessary to confirm this finding.Activity against NTS and adult S. mansoni in vitro
24 hours post-incubation all NTS exposed to 33.3 μM
FQ, FQ-OH and RQ showed strongly reduced viabilities.
72 hours post-incubation all NTS exposed to 33.3 μM
RQ had died, while FQ and FQ-OH treated worms were
strongly affected but still alive. Therefore, unlike for
P. falciparum and Trypanosoma brucei gambiense
[21], oxidative shock does not seem to play a role in the
activity of these compounds against S. mansoni, since
RQ, which cannot produce ROS is the most active of
the three organometallic drug against NTS in vitro.
This absence of redox activation could be explained by
the difference in the target of FQ, FQ-OH and RQ in
S. mansoni compared to P. falciparum. In P. falci-
parum, sour conditions present in the acidic compart-
ment where FQ localizes as well as of H2O2 are necessary
for the formation of HO. [12]. For comparison, no activity
was observed treating NTS with CQ at 33.3 μM (Figure 2a)
while at this concentration 24 hours post-incubation with
MQ all worms had died. The antischistosomal mechanism
of action of MQ and CQ is also not known. Note that
these 2 drugs do not produce hydroxyl radicals [22]. The
antimalarial activity of CQ and MQ is largely attributed to
an inhibition of hemoglobin degradation. However, it was
recently shown that hemozoin inhibition of CQ, MQ or
quinine does not exhibit a correlation with their antischis-
tosomal properties [23]. Furthermore, it was demonstrated
that MQ interferes with glycolysis in NTS [24].
Figure 2 Activity of ferroquine (FQ), hydroxy-ferroquine (FQ-OH), ruthenoquine (RQ), chloroquine (CQ) and mefloquine (MQ) versus
untreated control worms in vitro at 33.3 μg/ml against NTS (a) and adult S. mansoni (b).
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reduced motilities of NTS but the larvae did not die
(data not shown).
A similar trend was observed on adult S. mansoni. Incuba-
tion of adult S. mansoni with 33.3 μM of MQ resulted in
death of worms 24 h post-treatment, while adult S. mansoni
exposed to the organometallic derivatives were highly
affected in viability but were still alive 72 hours post-
incubation (Figure 2b). At 10 μM adults showed strongly
reduced viabilities 48–72 hours post-incubation with all de-
rivatives (data not shown).
Activity against adult S. mansoni in vivo
Compounds progressed into in vivo studies despite the
fact that in vitro activities were only observed at concen-
trations that were close to cytotoxic concentrations.However, in our recent studies MQ was well tolerated
by mice [8].
We have previously shown that CQ lacked antischisto-
somal activity in vivo (worm burden reduction of 11%) [8].
FQ is known for important and additional properties (e.g.
its higher lipophilicity) and mechanism of actions (the
above mentioned radical formation as well as hemozoin
inhibition) compared to CQ [22]. Yet, treatment of mice
with 200 and 800 mg/kg FQ, showed low total worm
burden reductions of 19.4% and 35.6% (Table 2). One of
the mice treated with 800 mg/kg FQ died within 24 hours
post-treatment. No activity was observed treating mice
with RQ at 200 mg/kg. Finally, a total worm burden
reduction of 17.3% was observed following treatment
with FQ-OH. Hence, modification of CQ by a ferroce-
nyl or ruthenocenyl fragment does not increase the
Table 2 Effect on worm burden of single oral doses of three selected organometallic CQ derivatives administered to mice harboring a 49-day-old adult
S. mansoni infection, stratified by sex and worm distribution
Drug Dose (mg/kg) No. of mice
investigated
No. of
mice cured
Mean number of worms (SD) Total worm burden
reduction (%)
p-value Female worm burden
reduction (%)
p-value
Liver Mesenteric
veins
Total Males Females
Control1 - 8 - 0.4 (0.7) 33.8 (10.2) 34.1 (10.3) 19.9 (7.7) 14.3 (4.2) - - - -
Control2 - 8 - 0.6 (1.2) 25.8 (16.7) 26.4 (16.7) 14.5 (9.3) 11.9 (7.7) - - - -
FQa 200 4 0 1.8 (2.4) 25.8 (7.3) 27.5 (7.3) 16.3 (4.9) 11.3 (4.0) 19.4 >0.05 21.0 >0.05
FQb 800 4* 0 0.7 (1.2) 16.3 (4.2) 17.0 (5.3) 10.3 (5.8) 6.7 (1.2) 35.6 >0.05 43.7 0.018
FQ-OHa,b 200 3 0 3.7 (5.5) 21.3 (26.6) 25.0 (24.4) 16.3 (14.3) 8.7 (10.8) 17.3 >0.05 33.6 >0.05
RQa 200 4 0 0.25 (0.5) 36.5 (10.7) 36.8 (10.4) 18.8 (5.3) 18.0 (5.3) 0 >0.05 0 >0.05
MQ 200 5 0 72.3 [8] 100
CQ 200 5 0 11.7 [8] 93.0
*one mouse died within 24 hours post-treatment, aworm burden reduction calculated versus control 1;bworm burden reduction calculated versus control 2SD= standard deviation.
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200 mg/kg MQ achieved a much higher worm burden
reduction of 72.3% in S. mansoni-infected mice [8]. A
few issues of our in vivo results are worth highlighting:
interestingly, a moderate female worm burden reduction
of 43.7% (p = 0.018) was observed using FQ at 800 mg/kg
(which had not been observed with CQ). A higher effect
against female adult S. mansoni was also observed in MQ
treated mice [8] pointing to a sex-specific interference of
these drugs with the target. Furthermore, in one of the
FQ-OH treated mice many dead worms were recovered
and a hepatic shift (i.e. worms migrating to the liver)
observed. Hence, FQ and FQ-OH show weak antischisto-
somal activity in vivo, which is in line with our in vitro
results.
Conclusions
In conclusion, the organometallic compounds evaluated
in this study show only weak antischistosomal properties
in vivo. Hence, based on our findings an ancillary benefit
on schistosomiasis as a result of treating P. falciparum
infections with FQ is not expected. Furthermore, no
correlation can be drawn between the antimalarial and
antischistosomal activity of CQ analogues, which might
hint to distinct mechanisms of actions. Despite the low
activities of organometallic drugs tested against S. mansoni
so far [25] further derivatives (e.g. organometallic deriva-
tives of MQ) should be studied.
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